I AMRN can get Ito tier 1 or 2 the generic threat would be lessoned and AMRNs value increased. Full speed ahead JT or whoever your replacement is going to be
Amarin Vascepa will be Tier 2, Lovaza or generic L will be tier 3. Negotiated price put them there . That dichotomy should be continued with any further competition.
The recognized value of current brand Vascepa in the body as well as in $$price should be a formidable barrier to any future Vascepa competition.